Full-Time
Precision Medicine Director
Updated on 9/3/2026
Novartis
10,001+ employees
Global pharmaceutical company delivering science-based innovations
Compensation Overview
€85.1k - €158.1k/yr
Barcelona, Spain
Hybrid
Hybrid working is required, and relocation support is not available; applicants should be able to access the Barcelona location.
 Biology & Biotech |
|---|
Get referred to Novartis
See people who can refer or advise you
- Significant experience in clinical research, clinical trials, or precision medicine within a life sciences environment.
- Proven experience leading cross-functional and multi-disciplinary teams.
- Strong understanding of biomarker strategies, companion diagnostics, and clinical development processes.
- Experience working within regulated environments and complying with global regulatory standards.
- Strong leadership, stakeholder management, and collaboration skills.
- Ability to manage risk and drive strategic decision-making.
- Experience developing clinical or regulatory documentation.
- Strong scientific and analytical capabilities within life sciences.
- Develop and execute precision medicine strategies aligned with disease area and clinical program objectives.
- Lead cross-functional biomarker sub-teams covering molecular epidemiology, assay development, and data analysis.
- Serve as a core member of global clinical teams and act as subject matter expert in precision medicine.
- Contribute to diagnostic target product profiles and companion diagnostic development strategies.
- Identify and manage risks to ensure successful delivery of precision medicine programs.
- Author biomarker and diagnostic sections of key clinical development documents.
- Support regulatory submissions as a precision medicine and biomarker expert.
- Facilitate collaborations with external academic and scientific partners.
- Ensure compliance with applicable medical device regulations and internal quality standards.
- Promote knowledge sharing and contribute to operational excellence and process improvement.
- Experience supporting global regulatory submissions for diagnostics or biomarker strategies.
- Experience working with external academic or research collaborations.
Novartis is a global pharmaceutical company that uses science-based innovations to develop treatments and improve patient outcomes worldwide. Its products are medicines developed through research and development to address various diseases, aiming to reach nearly 1 billion people. The company differentiates itself by large-scale investment in R&D, a global presence with a diverse workforce, and a clear mission to Reimagine Medicine, focusing on meeting the changing needs of patients. Its goal is to improve quality of life and extend life expectancy by delivering meaningful therapies through its research and development efforts.
Company Size
10,001+
Company Stage
IPO
Headquarters
Basel, Switzerland
Founded
1970
Get referred to Novartis
See people who can refer or advise you
Simplify's Take
What believers are saying
- Remibrutinib beat teriflunomide in REMODEL-1 and REMODEL-2 on September 1, 2026.
- Novartis signed Alteogen on September 2, 2026 for subcutaneous drug delivery rights.
- Second-quarter 2026 sales reached $14.41 billion and free cash flow hit $5.56 billion.
What critics are saying
- Pelacarsen failed Lp(a)HORIZON on September 4, 2026, crushing a cardiology growth pillar.
- Novartis paused eight rap-cel trials after three deaths, threatening its autoimmune-cell-therapy franchise.
- Entresto patent expiry looms while remibrutinib and delpacibart etedesiran still face regulatory execution.
What makes Novartis unique
- Novartis commercialized remibrutinib, now approved for CSU and winning in multiple sclerosis.
- Its global biologics network spans Europe and the United States, enabling rapid scale-up.
- Basel campus integration concentrates biologics development, manufacturing, and analytics under one operating system.
Help us improve and share your feedback! Did you find this helpful?
Benefits
Health Insurance
Dental Insurance
Vision Insurance
Life Insurance
Disability Insurance
401(k) Retirement Plan
401(k) Company Match
Paid Vacation
Paid Sick Leave
Paid Holidays
Hybrid Work Options
Growth & Insights and Company News
6 month growth
↓ -5%1 year growth
↓ -5%2 year growth
↓ -5%Novartis shares fell 1.9% in Zurich trading on Monday after its experimental drug pelacarsen failed a pivotal Phase 3 cardiovascular trial. The market wipeout erased approximately CHF4.9 billion from the Swiss pharmaceutical company's market capitalisation, according to Reuters estimates. The Lp(a)HORIZON trial enrolled 8,323 patients. Whilst pelacarsen successfully lowered lipoprotein(a) levels, it failed to significantly reduce cardiovascular deaths, heart attacks, strokes or urgent coronary procedures compared to placebo. Novartis reported second-quarter sales of $14.41 billion and generated $5.56 billion in free cash flow. The company's shares traded at $159.99, roughly 22.53% above analyst value estimates. Attention now turns to fourth-quarter data for del-desiran, acquired through Novartis's $12 billion purchase of Avidity, as investors seek pipeline validation.
Novartis, BMS pause autoimmune CAR-T trials after safety events. Novartis suspended several autoimmune and neurology trials of rap-cel after 3 patient deaths linked to immune effector cell-associated hemophagocytic syndrome, and BMS separately paused zola-cel studies after observing inflammatory safety events. Novartis has suspended several autoimmune and neurology trials of its investigational CD19 therapy rapcabtagene autoleucel (rap-cel) after 3 patients died following serious cases of immune effector cell-associated hemophagocytic syndrome (IEC-HS).[1,2] Bristol Myers Squibb has separately paused at least some studies of its own CAR-T candidate, zolacabtagene autoleucel (zola-cel), after observing transient and reversible inflammatory events in its autoimmune development program.[1,2] A Novartis spokesperson confirmed the suspension in a statement, saying the 3 IEC-HS cases led to complications that ultimately proved fatal.[1] The pause affects the phase 2 AUTOGRAPH studies evaluating rap-cel in systemic lupus erythematosus, systemic sclerosis, and idiopathic inflammatory myopathies (NCT06665256), along with phase 1/2 trials in rheumatoid arthritis and Sjogren disease (NCT07048197), generalized myasthenia gravis, and certain types of multiple sclerosis.[1] Studies of rap-cel in cancer are not affected by the pause.[1] Novartis is reviewing safety data as BMS acts out of caution. Novartis said it is analyzing safety data to identify the factors that may have contributed to the fatal complications and is working with independent data monitoring committees on enhanced safety measures, including tighter patient monitoring, earlier identification of adverse events, and improved management strategies.[1] BMS, describing its decision as a step taken out of an abundance of caution, confirmed it is voluntarily pausing at least some zola-cel studies to review clinical data across the therapy's development program.[1,2] The company has ongoing zola-cel trials across several autoimmune indications, including myasthenia gravis, multiple sclerosis, and rheumatoid arthritis, though it remains unclear whether the pause extends to all of them.[1] No deaths have been reported in connection with zola-cel; a single prior case of IEC-HS involving the therapy was described in results published in February from a phase 1 study.[2] "The drug's safety profile remains consistent with the known profile of CAR-T therapies," a BMS spokesperson said.[2] Analysts point to rapid manufacturing as a possible contributing factor. IEC-HS is a rare but serious adverse event previously reported with CD19 and BCMA-directed CAR-T therapies across blood cancer indications.[1] In a note to investors, analysts at William Blair pointed to rapid manufacturing, a feature shared by both rap-cel and zola-cel, as a possible contributor to the safety signals.[1] "Rapid manufacturing could be driving increased cell expansion and the reported toxicities," the analysts wrote, while also noting that indication-specific factors or a patient predisposition to a hyperinflammatory state could be playing a role.[1] The analysts cautioned that it remains difficult to extrapolate this risk to other CAR-T programs in development for autoimmune disease, noting that companies including Autolus, Cabaletta Bio, CRISPR Therapeutics, Kyverna Therapeutics, and Allogene Therapeutics are also developing CD19-directed CAR-T therapies for autoimmune indications.[1] Differentiated safety profiles among these competing programs could offer an advantage if development of the Novartis and BMS therapies remains constrained, according to the analysts.[1] Frequently asked questions. * What prompted Novartis to pause rap-cel trials in autoimmune disease? Three patients died after developing serious immune effector cell-associated hemophagocytic syndrome (IEC-HS) following treatment with rap-cel; the pause does not affect ongoing cancer studies of the therapy. * Why did BMS pause zola-cel studies? BMS voluntarily paused at least some zola-cel trials after observing transient and reversible inflammatory events, describing the move as a precaution while it reviews clinical data across the program; no deaths have been reported. * What might be driving these safety signals? Analysts have pointed to rapid manufacturing, a feature shared by both CAR-T candidates, as a possible contributing factor to increased cell expansion and toxicity, though indication-specific factors or patient predisposition may also play a role.
Novartis (NYSE:NVS) shares gap up - time to Buy? Novartis AG (NYSE:NVS - Get Free Report) gapped up prior to trading on Tuesday. The stock had previously closed at $152.06, but opened at $162.15. Novartis shares last traded at $161.64, with a volume of 1,164,231 shares. Stocks & Bonds Key Novartis news. Here are the key news stories impacting Novartis this week: * Remibrutinib cleared two Phase III multiple sclerosis trials. The oral drug significantly reduced annualized relapse rates versus teriflunomide (Aubagio) in relapsing multiple sclerosis and also showed favorable results on MRI lesion measures. Novartis said a combined analysis indicated a clinically meaningful delay in disability progression, strengthening the drug's potential commercial profile and supporting plans for global regulatory submissions. * The positive MS data are viewed as an important growth catalyst. Analysts and investors see remibrutinib as a potential future blockbuster in a large market, particularly because it outperformed an established treatment and reportedly showed no liver-safety signal. The results prompted a sharp prior-session rally and could improve confidence in Novartis' longer-term product pipeline. * Novartis signed a potential $3.2 billion Hybrozyme agreement with Alteogen. The deal could expand access to Alteogen's drug-delivery technology and support development or commercialization of future medicines, though the financial commitment and deal milestones may limit the near-term earnings benefit. * Novartis plans to relocate laboratory activities and shut down some Basel production operations, potentially affecting about 130 jobs. The restructuring may improve efficiency over time but creates near-term execution and employee-transition costs. * Novartis paused eight autoimmune and neurological cell-therapy trials after three patient deaths. The pauses raise safety, regulatory and development risks for the experimental rap-cel program and prompted a customer-related setback for Oxford BioMedica, though the issue is separate from remibrutinib. Wall street analyst weigh in. Several research analysts recently weighed in on NVS shares. Citigroup restated a "buy" rating on shares of Novartis in a research note on Wednesday, July 22nd. Weiss Ratings reiterated a "buy (b)" rating on shares of Novartis in a research note on Friday, July 24th. Seven investment analysts have rated the stock with a Buy rating, seven have given a Hold rating and two have given a Sell rating to the company's stock. According to data from MarketBeat, Novartis presently has an average rating of "Hold" and a consensus target price of $141.20. Discover more Exchange Traded Funds Novartis stock performance. The business's 50-day simple moving average is $155.48 and its two-hundred day simple moving average is $153.74. The company has a quick ratio of 0.67, a current ratio of 0.86 and a debt-to-equity ratio of 0.89. The firm has a market cap of $309.93 billion, a price-to-earnings ratio of 24.50, a P/E/G ratio of 3.14 and a beta of 0.45. Novartis (NYSE:NVS - Get Free Report) last posted its earnings results on Tuesday, June 30th. The company reported $2.41 EPS for the quarter. Novartis had a return on equity of 38.56% and a net margin of 23.29%.The firm had revenue of $14.95 billion for the quarter. As a group, sell-side analysts expect that Novartis AG will post 8.84 earnings per share for the current fiscal year. Institutional trading of Novartis. Institutional investors and hedge funds have recently made changes to their positions in the business. Morgan Stanley raised its position in Novartis by 14.9% during the fourth quarter. Morgan Stanley now owns 8,876,906 shares of the company's stock worth $1,223,860,000 after acquiring an additional 1,148,033 shares during the period. Fisher Asset Management LLC grew its position in shares of Novartis by 3.1% in the fourth quarter. Fisher Asset Management LLC now owns 7,465,850 shares of the company's stock valued at $1,029,317,000 after purchasing an additional 226,484 shares during the period. Bank of America Corp DE grew its position in shares of Novartis by 9.1% in the first quarter. Bank of America Corp DE now owns 4,962,794 shares of the company's stock valued at $758,067,000 after purchasing an additional 413,778 shares during the period. Auto Owners Insurance Co increased its stake in shares of Novartis by 13,687.0% during the fourth quarter. Auto Owners Insurance Co now owns 4,628,296 shares of the company's stock worth $638,103,000 after purchasing an additional 4,594,726 shares in the last quarter. Finally, Franklin Resources Inc. raised its position in shares of Novartis by 10.3% during the 4th quarter. Franklin Resources Inc. now owns 4,479,307 shares of the company's stock worth $617,562,000 after purchasing an additional 419,988 shares during the last quarter. 13.12% of the stock is currently owned by hedge funds and other institutional investors. About Novartis. Novartis is a Swiss multinational pharmaceutical company headquartered in Basel that researches, develops, manufactures and commercializes prescription medicines and related health-care products. Formed through the 1996 merger of Ciba-Geigy and Sandoz, Novartis operates globally and focuses on bringing therapeutics from discovery through clinical development to commercial markets worldwide. The company's activities center on innovative pharmaceuticals across several therapeutic areas, including oncology, immunology, cardiovascular and metabolic diseases, neuroscience and ophthalmology, alongside capabilities in advanced therapies such as biologics, cell and gene therapies. Receive News & Ratings for Novartis Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Novartis and related companies with MarketBeat.com's FREE daily email newsletter.
Novartis could cut about 130 jobs in Basel site relocation. Posted on September 2, 2026 · Last updated: September 2, 2026 Novartis plans to cut 130 Basel jobs in site relocation move. Novartis announces Basel job cuts amid site relocation. ZURICH, Sept 2 (Reuters) - Novartis could cut about 130 jobs in Switzerland as it relocates laboratory activities and shuts down some production in Basel, the Swiss drugmaker said on Wednesday. Details of the relocation plan. The company said it plans to transfer laboratories for biological cell banks, analytical testing procedures and technical development activities from Kleinbasel, an area of Basel, to its main campus in the city by the end of 2028. Laboratory transfers and production changes. As part of a previously planned relocation, Novartis will also stop small-scale production of biologics in Kleinbasel by the end of 2027. "We intend to move these activities to other existing biologics drug substance sites within our manufacturing network, specifically in Europe," the company told Reuters in an email. Alignment with lease expirations and development plans. The relocation aligns with the expiration of individual leases at the Kleinbasel site in 2029 and is part of a previously announced plan to establish a new biologics technical development centre on its main campus in Basel. The relocation was first announced in 2022 and currently, there are around 200 people employed at the site in Kleinbasel, the company said. Novartis investments and industry trends. Novartis has been investing heavily in sites in the United States as part of an industry-wide move to boost manufacturing in the country under pressure from the Trump administration. It plans to spend $23 billion to build and expand 10 facilities in the U.S. over the next five years. Impact on employees and support measures. The planned cessation of production in Kleinbasel and the resulting job cuts are subject to an information and consultation process, Novartis said. It added that it was committed to supporting affected employees through measures such as job centres, early retirement, and a social plan that has been extended until the end of 2028. Reporting credits. (Reporting by Marleen Kaesebier in Zurich and Bhanvi Satija in London Editing by Dave Graham, Kirsten Donovan) Key takeaways. * Around 130 jobs could be cut in Basel as Novartis centralises lab and production activities from Kleinbasel to its main campus by end-2028. (novartis.com) * Lab relocations (biological cell banks, analytical testing, technical development) will complete by end-2028; small-scale biologics production ceases by end-2027. (novartis.com) * Support measures include job centres, early retirement, and a social plan extended through end-2028; changes undergo consultation process. (novartis.com) * This aligns with lease expirations at Kleinbasel in 2029 and builds on Novartis's prior 2022 announcement to invest in biologics technical development on the main Basel campus. (novartis.com) * The shift reflects Novartis's broader strategy, including a $23 billion U.S. investment over five years to bolster its manufacturing and R&D footprint. (novartis.com) References. Frequently asked questions. How many jobs could Novartis cut in Basel? Why is Novartis relocating its Basel site? When will small-scale biologics production end in Kleinbasel? What support measures are in place for affected Novartis employees? Is the Novartis Basel relocation part of a larger investment strategy?
Novartis to cut up to 130 jobs in Basel. Published on September 2, 2026 The pharmaceutical company Novartis is cutting up to 130 jobs in Basel by the end of 2027. The reason, the company announced on Wednesday, is that it is discontinuing the small-scale production of biologics in the Kleinbasel district. In the future, other biologics sites around the world will take over the tasks of the Basel plant. The reason for discontinuing production is that individual lease agreements at the Kleinbasel site are coming to an end. Consequently, further operations will be relocated from the Kleinbasel district to the Novartis Campus on the opposite bank of the Rhine, according to the press release. These include laboratories for biological cell banks, analytical testing procedures and technical development activities. + Swiss pharma giant Novartis to cut over 500 jobs at Stein plant The move represents the next step in the previously announced plans to establish a new centre for the technical development of biologics on the campus, the press release continues. Full story here Are you the author? SWI swissinfo.ch - the international service of the Swiss Broadcasting Corporation (SBC). Since 1999, swissinfo.ch has fulfilled the federal government's mandate to distribute information about Switzerland internationally, supplementing the online offerings of the radio and television stations of the SBC. Today, the international service is directed above all at an international audience interested in Switzerland, as well as at Swiss citizens living abroad. 2026-05-06 Swiss drugmaker Novartis says it will cut around 220 jobs in Germany as part of the planned closure of a production site in Wehr by the end of 2028. +Get the most important news from Switzerland in your inbox Novartis says the production site in Wehr, Germany, which manufactures tablets and capsules, is no longer... 2026-05-04 Safaa Odah and Jimmy "Spire" Sseetongo are this year's winners of the Prix international de dessin de presse in Geneva. The Palestinian is being honoured for her humanitarian work in the Gaza Strip, the Ugandan for his cartoons critical of the government. + Get the most important news from Switzerland in your inbox "Our 2026... 2026-05-01 Development banks are becoming increasingly important in light of cuts to foreign aid by Western countries such as the United States and Switzerland. But how do these banks work, and what do they achieve for the Global South? Development banks are cooperative banks set up by states. Their aim is to promote development in other... 2026-04-30 The Swiss economy is showing timid signs of recovery, but does not yet appear to be at full strength: this is the indication that emerges from the barometer of the KOF Swiss Economic Institute. + Get the most important news from Switzerland in your inbox In April, the indicator stood at 97.9 points, 2.3 points... 2026-04-30 This is what it's about AI-generated, editorially reviewed High but steady salaries: The median full-time salary in Switzerland reached CHF 6,788 in 2022, continuing a long-term upward trend with relatively stable income distribution across earners since 2008. Inequality and differences persist: Salaries vary widely by region, education, industry, and gender - women still earn 9.5% less... 2026-04-27 The cyber threat environment in Switzerland has worsened significantly, an analysis by telecoms firm Swisscom has found. Artificial intelligence, geopolitical tensions and growing digital dependencies in particular are driving up risks for businesses. + Get the most important news from Switzerland in your inbox In a new report, Swiss telecoms provider Swisscom identified a significant... 2026-03-16 Swiss companies exported war materiel worth CHF948.2 million ($1.2 billion) in 2025. This means that last year's war materiel exports almost equalled the record figure of CHF955 million set in 2022. According to the State Secretariat for Economic Affairs (SECO), Germany was the largest buyer of the deliveries authorised by SECO in 2025, with exports... 2026-03-09 Vontobel has warned that Switzerland must avoid "over-regulation" as the government prepares to unveil sweeping reforms to its too-big-to-fail regime in the wake of Credit Suisse's collapse. Co-chief executive Christel Rendu de Lint, who leads one of Switzerland's larger listed banks and asset managers with CHF241 billion ($311 billion) in assets under management, said safeguarding...